Somewhat Favorable News Coverage Somewhat Unlikely to Affect Allergan (AGN) Stock Price

Media coverage about Allergan (NYSE:AGN) has been trending somewhat positive on Wednesday, Accern Sentiment Analysis reports. The research group rates the sentiment of press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. Allergan earned a news impact score of 0.20 on Accern’s scale. Accern also assigned media headlines about the company an impact score of 46.1481943639805 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the near term.

Here are some of the media headlines that may have impacted Accern’s rankings:

Allergan (NYSE AGN) traded down $1.28 during trading on Wednesday, reaching $159.31. 2,687,382 shares of the company were exchanged, compared to its average volume of 3,270,000. The company has a market capitalization of $53,050.00, a P/E ratio of -13.29, a P/E/G ratio of 1.16 and a beta of 1.19. Allergan has a 1-year low of $156.00 and a 1-year high of $256.80. The company has a current ratio of 2.04, a quick ratio of 1.88 and a debt-to-equity ratio of 0.41.

Allergan (NYSE:AGN) last released its earnings results on Tuesday, February 6th. The company reported $4.86 earnings per share for the quarter, beating analysts’ consensus estimates of $4.74 by $0.12. The business had revenue of $4.33 billion during the quarter, compared to the consensus estimate of $4.28 billion. Allergan had a negative net margin of 26.32% and a positive return on equity of 8.28%. The firm’s revenue for the quarter was up 12.0% compared to the same quarter last year. During the same quarter last year, the firm earned $3.90 earnings per share. analysts predict that Allergan will post 15.57 earnings per share for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, March 28th. Investors of record on Wednesday, February 28th will be given a $0.72 dividend. The ex-dividend date of this dividend is Tuesday, February 27th. This represents a $2.88 dividend on an annualized basis and a yield of 1.81%. This is an increase from Allergan’s previous quarterly dividend of $0.70. Allergan’s dividend payout ratio (DPR) is -23.35%.

AGN has been the topic of several analyst reports. Royal Bank of Canada set a $250.00 target price on shares of Allergan and gave the stock a “buy” rating in a report on Sunday, October 29th. They noted that the move was a valuation call. Cantor Fitzgerald set a $231.00 target price on shares of Allergan and gave the stock a “hold” rating in a report on Wednesday, November 1st. Wells Fargo & Co reiterated an “outperform” rating and issued a $245.00 target price (down from $258.00) on shares of Allergan in a report on Thursday, November 2nd. Morgan Stanley cut their target price on shares of Allergan from $228.00 to $200.00 and set an “equal weight” rating on the stock in a report on Thursday, November 2nd. Finally, Leerink Swann reiterated an “outperform” rating and issued a $237.00 target price on shares of Allergan in a report on Monday, November 27th. Two analysts have rated the stock with a sell rating, seven have issued a hold rating and fourteen have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $227.23.

In other Allergan news, Director Christopher J. Coughlin bought 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, December 5th. The stock was acquired at an average price of $163.30 per share, with a total value of $1,633,000.00. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider William Meury sold 11,807 shares of the firm’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $173.89, for a total transaction of $2,053,119.23. The disclosure for this sale can be found here. In the last ninety days, insiders purchased 17,630 shares of company stock valued at $2,890,057. 0.36% of the stock is owned by insiders.

TRADEMARK VIOLATION WARNING: This piece was first reported by BBNS and is owned by of BBNS. If you are reading this piece on another site, it was illegally copied and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be viewed at https://baseballnewssource.com/markets/somewhat-favorable-news-coverage-somewhat-unlikely-to-affect-allergan-agn-stock-price/1899474.html.

Allergan Company Profile

Allergan, Inc is a multi-specialty healthcare company. The Company focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter (OTC) products. It discovers, develops and commercializes a range of products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets.

Insider Buying and Selling by Quarter for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Three-Way Trade Sends Souza to Diamondbacks and Drury to Yankees
Three-Way Trade Sends Souza to Diamondbacks and Drury to Yankees
Eric Hosmer Agrees to Eight-Year Deal with San Diego Padres
Eric Hosmer Agrees to Eight-Year Deal with San Diego Padres
Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Report: Eduardo Nunez and Red Sox Agree to Deal for One Year
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Los Angeles Angels Plan to Use Shohei Ohtani in Six-Man Rotation
Cubs Sign Free Agent Yu Darvish
Cubs Sign Free Agent Yu Darvish
Mother of Pittsburgh Pirates Player Elias Diaz Has Been Kidnapped
Mother of Pittsburgh Pirates Player Elias Diaz Has Been Kidnapped


Leave a Reply

 
© 2006-2018 BBNS.